Roche Highlights its Bispecific Antibody Portfolio Across a Range of Blood Cancers at ASH 2020
Shots:
- The company presented the new data of its T-cell engaging bispecific Abs- mosunetuzumab- glofitamab and cevostamab at ASH 2020- demonstrating encouraging activity across multiple types of blood cancer
- Roche divulges that its mosunetuzumab & glofitamab showed promising responses across multiple types of NHL- including R/R FL & DLBCL- reinforcing from the P-I/Ib GO29781 study results in R/R FL- that showed 51.6% of patients achieved a CR when treated with mosunetuzumab
- Beyond r/r setting- mosunetuzumab & glofitamab are also being evaluated in 1L DLBCL. Additionally- Roche has presented the data of cevostamab that showed a 53% ORR rate in heavily pre-treated patients with MM
Ref: GlobeNewswire | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com